Abstract
Ever-increasing attention is being paid worldwide to the safety of medical products, and the risks associated with their use. The integral role of risk communication in overall risk management is demonstrated by several recent market withdrawals of drugs, in which a perceived incapability of healthcare systems to manage well-characterised, avoidable risks was a significant factor.
With advances in clinical pharmacology, pharmacogenomics and pharmacoepidemiology expanding our knowledge of medical products, effective delivery of the latest safety-related information to health professionals and consumers becomes even more imperative. In this regard, it is important to evaluate whether current modes of risk communication lead to desired changes in relevant behaviours such as prescribing or drug monitoring, particularly in context with which achieved level of effectiveness is deemed acceptable. This is crucial, as there have been product-specific risk communication efforts that achieved a fair degree of success, yet were not seen as effective enough to prevent market withdrawal of the medical product in question.
In the service of improving public health through enhanced risk communication, it is essential to critically assess current methods, both as to results achieved (or not), and whether each method is applicable to the various types of risks associated with medical product use. Furthermore, just as combining methods may well improve overall risk communication, there are societal and psychological factors that must be considered in attempting to maximise effectiveness. However, in assessing risk communication effectiveness, the particular benefit-risk relationship of any individual medical product must also be part of the evaluative process.
Similar content being viewed by others
References
Task Force on Risk Management. Report to the FDA Commissioner: managing the risks from medical product use: creating a risk management framework. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, 1999 May
International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guideline E2A: clinical safety data management: definitions and standards for expedited reporting [online]. Available from URL: http://www.ich.org/UrlGrpServer.jser?.@_ID=276&@_TEMPLATE=254 [Accessed 2004 Jan 25]
CIOMS IV Working Group. Benefit-risk balance for marketed drugs: evaluating safety signals. Geneva: Council For International Organizations Of Medical Sciences, 1998
Presidential/Congressional Commission on Risk Assessment and Risk Management. Framework for environmental health risk management: final report, vol. 1. 1997
Bates DW, Leape LL, Petrycki S. Incidence and preventability of adverse drug events in hospitalized adults. J Gen Intern Med 1993; 8: 289–94
US Department of Health and Human Services, Food and Drug Administration. Notice of public workshop, request for comments. Fed Regist 2003 Mar 7; 68 (45): 11120–1
CDER/CBER Risk Assessment Working Group. Rockville, MD. US Department of Health and Human Services, Food and Drug Administration. 3 Mar 2003. Available from URL: http://www.fda.gov/cder/meeting/riskmanagement.htm [Accessed 2004 Jan 25]
Honig P, Phillips J, Woodcock J. How many deaths are due to medical errors? [letter]. JAMA 2000 Nov 1; 284(17): 2187–8
van Grootheest ACK, Edwards IR. Labelling and ‘Dear Doctor’ letters: are they noncommittal? Drug Saf 2002; 25(15): 1051–5
Seligman PJ. ‘Dear Doctor…’- evaluating the impact of risk communication efforts. Pharmacoepidemiol Drug Saf 2003 Jun; 12(4): 291–3
Honig PK, Woosley RL, Zamani K, et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992 Sep; 52(3): 231–8
Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences. JAMA 1993 Mar 24/31; 269(12): 1513–8
Woosley RL, Chen Y, Freiman JP, et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993 Mar 24/31; 269(12): 1532–6
Burkhart GA, Sevka MJ, Temple R, et al. Temporal decline in filling prescriptions for terfenadine closely in time with those for either ketoconazole or erythromycin. Clin Pharmacol Ther 1997 Jan; 61(1): 93–6
Thompson D, Oster G. Use of terfenadine and contraindicated drugs. JAMA 1996 May 1; 275(17): 1339–41
Carlson AM, Morris LS. Coprescription of terfenadine and erythromycin or ketoconazole: an assessment of potential harm. J Am Pharm Assoc (Wash) 1996 Apr; NS36(4): 263–9
Cavuto NJ, Woosley RL, Sale M. Pharmacies and prevention of potentially fatal drug interactions [letter]. JAMA 1996 Apr 10; 275(14): 1086
US Food and Drug Administration. FDA proposes to withdraw Seldane approval [Talk Paper]. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, 1997 Jan 13
Klausner MA. Dear doctor letter. Titusville (NJ): Janssen Pharmaceutica Research Foundation, 1998 Jun 26
US Food and Drug Administration. FDA strengthens warning label for Propulsid [Talk Paper]. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, 1998 Jun 29
Smalley W, Shatin D, Wysowski DK, et al. Contraindicated use of cispapride: impact of Food and Drug Administration regulatory action. JAMA 2000 Dec 20; 284(23): 3036–9
Weatherby LB, Walker AM, Fife D, et al. Contraindicated medications dispensed with cispapride: temporal trends in relation to the sending of ‘Dear Doctor’ letters. Pharmacoepidemiol Drug Saf 2001 May; 10(3): 211–8
Jones JK, Fife D, Curkendall S, et al. Coprescribing and codispensing of cispapride and contraindicated drugs. JAMA 2001 Oct 3; 286(13): 1607–9
De Bruin ML, Panneman MJM, Leufkens HGM, et al. Use of cispapride with contraindicated drugs in The Netherlands. Ann Pharmacother 2002 Feb; 36: 338–43
Centrale Medisch Pharmaceutische Commissie. Farmacotherapeutisch Kompas 1999. Amstelveen, Netherlands: Ziekenfondsraad, 1999
McMullin ST, Reichley RM, Watson LA, et al. Impact of a Web-based clinical information system on cisapride drug interactions and patient safety. Arch Intern Med 1999 Sep 27; 159: 2077–82
Cahill JA. Responsibilities of physicians and pharmacists in preventing drug interactions [letter]. JAMA 2002 Feb 6; 287(5): 586
US Food and Drug Administration. Janssen Pharmaceutica stops marketing cisapride in the US [Talk Paper]. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, 2000 Mar 23
de Vane PJ. Dear health care professional letter. Bronx (NY): Wyeth-Ayerst Laboratories, 1998 Feb
US Food and Drug Administration. Warning label changes for pain reliever Duract [Talk Paper]. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, 1998 Feb 10
US Food and Drug Administration. Wyeth-Ayerst Laboratories announces the withdrawal of Duract from the market [Talk Paper]. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, 1998 Jun 22
Friedman MA, Woodcock J, Lumpkin MM, et al. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA 1999 May 12; 281(18): 1728–34
US Food and Drug Administration, Center for Drug Evaluation and Research. Drug Approvals for January 1997. Available from URL: http://www.fda.gov/cder/da/da0197.htm [Accessed 2004 Feb 20]
US Department of Health and Human Services. HHS News: Rezulin to be withdrawn from the market. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, 2000 Mar 21
Sigmund II WR. Dear healthcare professional letter. Morris Plains (NJ): Parke-Davis, 1997 Oct 28
Sigmund II WR. Dear healthcare professional letter. Morris Plains (NJ): Parke-Davis, 1997 Dec 1
Sigmund II WR. Dear healthcare professional letter. Morris Plains (NJ): Parke-Davis, 1998 Jul 28
Sigmund II WR. Dear healthcare professional letter. Morris Plains (NJ): Parke-Davis, 1999 Jun 16
Graham DJ, Drinkard CR, Shatin D, et al. Liver enzyme monitoring in patients treated with troglitazone. JAMA 2001 Aug 15; 286(7): 831–3
Pierce M. Presentation at Endocrinologic and Metabolic Drugs Advisory Committee, 1999 Mar 26. Available from URL: http://www.fda.gov/ohrms/dockets/ac/99/transcpt/3499t1c.pdf [Accessed 2004 Apr 13]
Sturkenboom MCJM, de Jong-van den Berg LTW, Cornel MC, et al. Communicating a drug alert: a case study on acitretin in The Netherlands. Eur J Clin Pharmacol 1994; 47: 125–32
Howard WB, Willhite CC. Toxicology of retinoids in humans and animals. J Toxicol Toxin Rev 1986; 5: 55–96
DiGiovanna JJ, Zech LA, Ruddel ME, et al. Etretinate: persistent serum levels after long-term therapy. Arch Dermatol 1989 Feb; 125(2): 246–51
Lumpkin MM. FDA Public Health Advisory. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, 1997 Dec 15
US Food and Drug Administration. Q & A’s: low molecular weight heparins/ heparinoids and spinal/epidural anesthesia. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, 1998 May 6
US Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health. Promoting and protecting the public health: annual report fiscal year 1999. Available from URL: http://www.fda.gov/cdrh/annual/annualreport99.html [Accessed 2004 Feb 15]
Jacobson ED. Potential cross-contamination linked to hemodialysis treatment [Safety Alert]. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, 1999 May
Feigal Jr DW, Woodcock J. Potential for injury from medical gas misconnections of cryogenic vessels [Public Health Advisory]. Rockville (MD): US Department of Health and Human Services, Food and Drug Administration, 2001 Jul 20
US Food and Drug Administration, Center for Devices and Radiological Health. Safety Alerts, Public Health Advisories and notices from CDRH. Available at URL: http://www.fda.gov/cdrh/safety.html [Accessed 2004 Jan 5]
Weatherby LB, Nordstrom BL, Fife D, et al. The impact of wording in “Dear doctor” letters and in black box labels. Clin Pharmacol Ther 2002 Dec; 72(6): 735–42
Guo JJ, Curkendall S, Jones JK, et al. Impact of cispapride label changes on codispensing of contraindicated medications. Pharmacoepidemiol Drug Saf 2003 Jun; 12(4): 295–301
Soumerai SB, Avorn J. Principles of educational outreach (‘academic detailing’) to improve clinical decision making. JAMA 1990 Jan 26; 263(4): 549–56
Manning PR, Lee PV, Clintworth WA, et al. Changing prescribing practices through individual continuing education. JAMA 1986 Jul 11; 256(2): 230–2
Anderson GM, Lexchin J. Strategies for improving prescribing practice. CMAJ 1996 Apr 1; 154(7): 1013–7
Grimshaw JM, Shirran L, Thomas R, et al. Changing provider behavior: an overview of systematic reviews of interventions. Med Care 2001 Aug; 39(8 Suppl. 2): II2–45
May FW, Rowett DS, Gilbert AL, et al. Outcomes of an educational-outreach service for community medical practitioners: non-steroidal anti-inflammatory drugs. Med J Aust 1999 May; 170(10): 471–4
Roughead EE, Gilbert AL, Primrose JG. Improving drug use: a case study of events which led to changes in use of flucloxacillin in Australia. Soc Sci Med 1999; 48: 845–53
Derby LE, Jick H, Henry DA, et al. Cholestatic hepatitis associated with flucloxacillin. Med J Aust 1993 May 3; 158(9): 596–600
Jick H, Derby LE, Dean AD, et al. Flucloxacillin and cholestatic hepatitis [letter]. Med J Aust 1994 Apr 18; 160(8): 525
Fairley CK, McNeil JJ, Desmond P, et al. Risk factors for development of flucloxacillin associated jaundice. BMJ 1993 Jan 23; 306(6872): 233–5
Department of Human Services and Health. Schedule of pharmaceutical benefits for approved pharmacists and medical practitioners, August 1993. Canberra: Australian Government Publishing Service, 1993
Department of Human Services and Health. Schedule of pharmaceutical benefits for approved pharmacists and medical practitioners, August 1994. Canberra: Australian Government Publishing Service, 1994
Edwards IR, Hugman B. The challenge of effectively communicating risk-benefit information. Drug Saf 1997 Oct; 17(4): 216–27
Scott HD, Thacher-Renshaw A, Rosenbaum SE, et al. Physician reporting of adverse drug reactions: results of the Rhode Island Adverse Drug Reaction Reporting Project. JAMA 1990 Apr 4; 263(13): 1785–8
Schlienger RG, Luscher TF, Schoenenberger RA, et al. Academic detailing improves identification and reporting of adverse drug events. Pharm World Sci 1999; 21(3): 110–5
Juergens JP, Szeinbach SL, Janssen MJ, et al. An evaluation of interventions designed to stimulate physician reporting of adverse drug events. Top Hosp Pharm Manage 1992 Jul; 12(2): 12–8
Goldman SA, Lieberman R, Kausal DJ. Teaching healthcare professionals about drug-induced disease: an innovative clinical therapeutic approach. J Clin Pharmacol 1996 May; 36(5): 386–96
Goldman SA, Kennedy DL, Lieberman R, editors. Clinical therapeutics and the recognition of drug-induced disease [MedWatch Continuing Education Article]. Rockville (MD): Food and Drug Administration, 1995 Jun. Available from URL: http://www.fda.gov/medwatch/articles.htm [Accessed 2004 May 10]
Goldman SA. Use of a mail-out continuing education article to teach health professionals about drug-induced disease. J Clin Pharmacol 1999 Nov; 39(11): 1126–35
Goldman SA. The clinical impact of adverse event reporting [MedWatch Continuing Education Article]. Rockville (MD): Food and Drug Administration, 1996 Oct. Available from URL: http://www.fda.gov/medwatch/articles.htm [Accessed 2004 May 10]
White GG, Weick-Brady MD. Improving patient care by reporting problems with medical devices [MedWatch Continuing Education Article]. Rockville (MD): Food and Drug Administration, 1997 Sep. Available from URL: http://www.fda.gov/medwatch/articles.htm [Accessed 2004 May 10]
Alaszewski A, Horlick-Jones T. How can doctors communicate information about risk more effectively? BMJ 2003 Sep 27; 327(7417): 728–31
Gigerenzer G, Edwards A. Simple tools for understanding risks: from innumeracy to insight. BMJ 2003 Sep 27; 327(7417): 741–4
Aronson JK, Derry S, Loke YK. Adverse drug reactions: keeping up to date. Fundam Clin Pharmacol 2002 Feb; 16(1): 49–56
Acknowledgements
No funding was obtained from any source specific to the preparation of this manuscript. In the course of the author’s career in medical product safety, he has been a full-time employee of both the US Food and Drug Administration FDA) and Knoll Pharmaceutical Company (Abbott Laboratories), and acted as a consultant to pharmaceutical companies. During the author’s tenure at FDA, he served on the Task Force on Risk Management that is described in the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Goldman, S.A. Communication of Medical Product Risk. Drug-Safety 27, 519–534 (2004). https://doi.org/10.2165/00002018-200427080-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-200427080-00005